Anthony Linton

Anthony Linton is a male medical professional who specializes in treating conditions like Mesothelioma, Lung Cancer, and Prostate Cancer.

He helps patients by using special skills and treatments to improve their health.

Anthony Linton communicates with patients in a caring and respectful way, which helps patients trust him with their care.

He stays updated with the latest medical knowledge and research to provide the best possible treatment for his patients.

Anthony Linton works well with his colleagues and other medical professionals, collaborating to ensure the best outcomes for patients.

His work has positively impacted many patients' lives, improving their health and well-being.

One of his notable publications is titled "A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma," published in the Journal of experimental & clinical cancer research on September 18, 2024.

He has also conducted a clinical trial called "MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor-Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy," which has been completed.

Overall, Anthony Linton is a dedicated and knowledgeable medical professional who works tirelessly to improve the lives of his patients through his expertise and commitment to staying at the forefront of medical advancements.